Anixa Biosciences’ (ANIX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research note released on Tuesday,Benzinga reports. HC Wainwright currently has a $7.00 price target on the stock.

Separately, EF Hutton Acquisition Co. I upgraded shares of Anixa Biosciences to a “strong-buy” rating in a research note on Wednesday, August 7th.

Anixa Biosciences Stock Up 2.3 %

ANIX stock opened at $3.12 on Tuesday. The company has a market cap of $100.40 million, a price-to-earnings ratio of -8.00 and a beta of 0.84. The business has a fifty day simple moving average of $3.26 and a 200-day simple moving average of $2.99. Anixa Biosciences has a 52 week low of $2.14 and a 52 week high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Friday, September 6th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. As a group, analysts expect that Anixa Biosciences will post -0.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Anixa Biosciences

A number of large investors have recently modified their holdings of ANIX. Nations Financial Group Inc. IA ADV boosted its holdings in Anixa Biosciences by 50.0% in the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock worth $50,000 after acquiring an additional 7,500 shares during the period. Virtu Financial LLC grew its holdings in Anixa Biosciences by 47.2% during the 1st quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after purchasing an additional 5,183 shares in the last quarter. International Assets Investment Management LLC increased its stake in Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after buying an additional 23,800 shares during the period. Concorde Asset Management LLC acquired a new position in Anixa Biosciences in the 2nd quarter worth $31,000. Finally, Tyler Stone Wealth Management boosted its position in Anixa Biosciences by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after buying an additional 21,008 shares during the last quarter. Institutional investors and hedge funds own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.